CAR T cell therapy for multiple myeloma: Where are we now and where are we headed? Journal Article


Authors: Ghosh, A.; Mailankody, S.; Giralt, S. A.; Landgren, C. O.; Smith, E. L.; Brentjens, R. J.
Article Title: CAR T cell therapy for multiple myeloma: Where are we now and where are we headed?
Abstract: While recent progress has been made in the management of multiple myeloma, it remains a highly fatal malignancy especially among patients with relapsed-refractory disease. Immunotherapy with adoptive T cells targeting myeloma-associated antigens are at various stages of development and have brought about a new hope for cure. This is a review on the emerging field of adoptively transferred engineered T cell based approaches, with an in-depth focus on chimeric antigen receptors (CAR) targeting multiple myeloma. The recent results from CAR T cells targeting B cell maturation antigen are encouraging but eventual resistance to the CAR T cell therapies remain problematic. With newer approaches in therapies for multiple myeloma, the role of transplantation is evolved to form a platform for T cell therapies. © 2017, © 2017 Informa UK Limited, trading as Taylor & Francis Group.
Keywords: multiple myeloma; immunotherapy; tcr; hematopoietic cell transplantation; chimeric antigen receptors; car; bcma
Journal Title: Leukemia and Lymphoma
Volume: 59
Issue: 9
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2018-01-01
Start Page: 2056
End Page: 2067
Language: English
DOI: 10.1080/10428194.2017.1393668
PROVIDER: scopus
PMCID: PMC5936668
PUBMED: 29105517
DOI/URL:
Notes: Review -- Export Date: 4 September 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Renier J Brentjens
    187 Brentjens
  2. Sergio Andres Giralt
    499 Giralt
  3. Arnab Ghosh
    39 Ghosh
  4. Eric Smith
    26 Smith
  5. Carl Ola Landgren
    175 Landgren